Loading
Saturday, October 17, 2026 · Vol. I, No. 42Independent · Canadian · Research-first
Before you compare Canadian research sourcesRun the free 10-point COA + batch audit at LynxLabs →
Thymosin alpha-1 · research summary
Clinical case reports · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.
Case report
“To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune‐related adverse events (irAEs) after treatment with sintilimab (PD‐1 inhibitor) in combination with thymosin alpha‐1 (Tα1).”
A 29-year-old male with stage cT4N3M0 nasopharyngeal carcinoma
“A 29‐year‐old male (weight 84 kg) was diagnosed with stage cT4N3M0 nasopharyngeal carcinoma in April 2024.”
Sintilimab was reintroduced 3-5 months after discharge without recurrence of serious immune-related adverse events.
“Approximately 3–5 months after discharge, sintilimab was reintroduced at 200 mg every 3 weeks for six cycles; no further serious irAEs occurred, and the patient remained in stable disease.”
Source: PubMed 41669704 · DOI 10.1002/ccr3.72025 · all study summaries